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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Does 
Fecal Microbiota Transplantation cause Clinical Remission in Patients with Ulcerative Colitis?” 
 
Study Design: Review of three English language primary studies published in 2015. 
 
Data Sources: Two randomized control trials and a cohort study determining if fecal microbiota 
transplantation does lead to clinical remission of Ulcerative Colitis were found by using PubMed 
and Cochrane databases.  
 
Outcome(s) Measured: The outcomes measured in all three studies were patient oriented 
evidence that matters which is clinical remission. The outcomes in the Moayyedi et al. was 
measured by the Mayo Score The Rossen et al. study determined clinical remission as SCCAI 
score ≤ 2 in combination with ≥1 point improvement on the combined Mayo endoscopic score 
of the sigmoid and rectum, compared to the baseline sigmoidoscopy, 12 weeks after the first 
treatment. The Wei et al. trail determined clinical remission was defined as IBDQ >170 and 
Mayo score <2 in Ulcerative Colitis.  
 
Results: This review compares two randomized, double blind, placebo controlled clinical trials 
and one cohort study in which the Moayyedi et al. and Wei et al. trial proved that Fecal 
microbiota transplantation is effective in providing clinical remission in patients with active 
Ulcerative Colitis; however, the Rossen et al. trial showed there was no significant statistical 
difference between the experimental [FMT-D] and the placebo [FMT-A] group in inducing 
clinical remission in patients with active Ulcerative Colitis.  
 
Conclusions: Fecal Microbiota Transplantation does seem to provide effective treatment in 
causing clinical remission of Ulcerative Colitis overall according to the three studies in this 
review. 
 
Key Words: fecal microbiota, Ulcerative Colitis
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INTRODUCTION 
Ulcerative Colitis results from an abnormal response by the body’s immune system. The 
immune system normally contains proteins and cells that protect the body from infection; 
however, in Ulcerative Colitis, the immune system mistakes food, bacteria, and other material in 
the intestine as foreign or infectious substances.1 This immune system impairment leads to a 
chronic disease of the colon in which the mucosal lining of the colon becomes inflamed, leading 
to diffuse friability and erosions which result with open sores or ulcers producing pus, mucus, 
and bleeding.2 Patients with ulcerative colitis usually present with bloody diarrhea. Bowel 
movements are frequent and small in volume as a result of rectal inflammation. Some other 
associated symptoms include colicky abdominal pain, urgency, tenesmus, and incontinence. 
Patients with mainly distal disease may have constipation accompanied by frequent discharge of 
blood and mucus.3 Although considerable progress has been made in IBD research, investigators 
do not yet know what causes this disease. 
Ulcerative colitis affects 907,000 people in the United States, and is currently on the rise 
with 38,000 new cases each year.4 Men and Women are equally likely to be affected, with most 
diagnosed in their mid-30s.4 However, Ulcerative Colitis can occur at any age and recent studies 
showed older men are more likely to be diagnosed than older women.4 The annual direct cost 
based on US insurance claims data from 2003-2004 is $5,066 per patient, indirect costs were 
$5,228 per patient, and the annual financial burden of IBD in the US may be more than $31 
billion.4 
Currently there is no definitive cure for Ulcerative Colitis but there are medications 
currently out to provide symptomatic relief to treat the disease. The initial therapy for a patient 
with Ulcerative Colitis is patient education; eat regular diet but limit intake of caffeine and gas-
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producing vegetables. Anti-diarrheal agents should not be given in the acute phase of the illness 
but are safe and helpful in patients with mild chronic symptoms.  For symptomatic relief, 
medications are taken such as oral 5-ASA agents such as mesalamine, balsalazide, or 
sulfasalazine. If no improvement is seen on 5-ASA after 4-8 weeks of improvement then add on 
corticosteroids such as prednisone or methylprednisolone. Patients not responding to 5-ASA or 
corticosteroids or for corticosteroid-dependent patients give immunomodulators such as 
Mercaptopurine or azathiopurine or an Anti- TNF like Infliximab. If all these medications don’t 
work then last resort is surgery to remove the diseased portion of the colon.2  
In Ulcerative Colitis the composition of the microbiota is different in that of a healthy 
individual in that the diversity is lower and contains lower number of Clostridium clusters and 
Bacteriodes. It is unclear if this disturbed microbiota is the cause or result of UC.5 Fecal 
microbiota transplantation may offer a method of enriching the gut microbiota leading to 
remission of Ulcerative Colitis. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not fecal microbiota 
transplantation cause clinical remission in patients with Ulcerative Colitis. 
 
 
METHODS 
 These three studies, two randomized controlled trials and one cohort study, this 
systematic review was based on the population age, the intervention, and the outcomes 
measured. The populations of the research article were all adults, both males and females, ages 
18-70 year old, diagnosed with active or established Ulcerative Colitis. The common 
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intervention among all studies was transplantation of fecal microbiota. The demographics and 
characteristics of each study are displayed in Table 1. For the study by Moayeddi et al, the 
comparison groups were patients with Ulcerative Colitis given Fecal Microbiota Transplantation 
(FMT) from healthy donor versus Patient given a placebo.6 Patients were randomized in this 
study to either receive 50 mL of FMT or a placebo of 50 mL of water given as a retention enema 
once per week for a total of 6 weeks. On the seventh week, patients returned to complete the 
final Mayo Clinic Score, Inflammatory Bowel Disease Questionnaire (IBDQ) and an exit 
sigmoidoscopy to compare to the baseline scores.6 In the Wei et al study, there was no 
comparison study and just measured the results of patients receiving FMT over a 4 week period. 
The way this transplantation procedure took place was the participants were maintained on 500 
mg of vancomycin twice a day, for three consecutive days 12 hours before the Fecal Microbiota 
Transplantation (FMT). On the day before the procedure participants also took polyethylene 
glycol to wash out any fecal material and then the 300 mL donor material was administered by a 
colonoscopy’s biopsy channel.7 In the Rossen et al study, the comparison groups were patients 
with Ulcerative Colitis, were randomized either receiving 2 duodenal infusions of donor feces 
from healthy host [FMT-D] or 2 duodenal infusions of autologous feces [FMT-A] which served 
as a control in participants receiving their own feces. This was administered via nasoduodenal 
tube. Prior to the administration, patients were pretreated with bowel lavage the evening and 
morning before the treatment to washout much of the particpants indigenous microbiota.5 Three 
weeks later the same procedure was repeated and the outcomes were measured at week 12. The 
outcome in these 3 studies, which were important, was Clinical Remission that qualifies as 
patient oriented evidence that matters (POEM). 
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Keywords used in the searches were “fecal microbiota and Ulcerative Colitis.” All 
articles were published in peer-reviewed journals in the English language. The articles were 
searched through the Cochrane databases and through PubMed. The articles were patient 
oriented evidence that matters (POEM). Inclusion criteria for this study is randomized control 
trials and cohort studies based on patient oriented evidence that matters, patients aged 18 or older 
with active Ulcerative Colitis defined as Mayo Clinic The exclusion criteria for this study are 
patients under the age of 18, articles that were not randomized double blind, articles without 
placebo controlled trails, and disease oriented trials. The statistics reported in this study were p-
values, Relative Benefit Increase (RBI), Absolute Benefit Increase(ABI), number needed to treat 
(NNT).  
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Table 1: Demographics & Characteristics of included studies 
Study Type #pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria w/d Intervention 
Moayyed
i P 
(2015) 
Randomi
zed  
Controll
ed 
Study 
(RCT) 
75 18-60 -Eligible Patients were 18 
years or older with active 
Ulcerative Colitis defined as 
Mayo Clinic Score 4 with an 
endoscopic Mayo Clinic 
Score 1. 
- Concomitant treatment for 
UC, such as mesalamine, 
glucocorticoids, 
immunosuppressive therapy, 
or tumor necrosis factor 
antagonists were permitted, 
provided these had been used 
for at least 12 weeks( 4 weeks 
for glucocorticoids) and 
disease remained active. 
- 5 patients who were 
previously exposed to 
mesalamine or steroids had a 
30 day washout period before 
being enrolled.	
 
Pt taken antibiotics or probiotics in 
last 30 days, had concomitant C 
difficile infection or another enteric 
pathogen, had a disease severity that 
required hospitalization, were 
pregnant, or were unable to give 
informed consent. 
 
5 Fecal 
Microbiota 
Transplantation 
by Healthy 
Donor 
(Retention 
Enema 
Approach) 
Wei Y 
(2015) 
Cohort 
Study 
11 24-70 -Age Range 18-70y/o 
-CDAI Score of 150 and 400; 
or Mayo score(UCDAI) of 2-
10. 
 
-Pregnant  
- End-Stage Disease 
- If pts participating in other trials 
within 3 months prior to 
transplantation. 
If infectious colitis 
- Pt scheduled for abdominal surgery  
- If pt took 
probiotics/prebiotics/synbiotics/antib
iotic/PPI orally in the last month 
- If pt suffer from severe anemia, 
heart cerebrovascular accident, and 
bypass or underwent stent 
implantation last 6 months 
- If pt has coagulation disorders or 
immune suppression status or 
underwent abdominal transplant last 
3 months. 
- If pt took TNF monoclonal 
antibody 2 months before 
transplantation or planned to take it 
within one month after 
transplantation. 
- If pt had history of megacolon. 
 
1 Fecal 
transplantation 
from healthy 
donors (via 
colonoscopy 
biopsy channel 
in UC cases) 
 
Rossen 
(2015) 
Randomi
zed  
Controll
ed 
Study 
(RCT) 
50 30-56 - Established Ulcerative 
Colitis according to the 
Leonard Jones Criteria, a pt 
reported SCCAI of  ≥4 and 
≤11 and stable medication, 
which was continued during 
the study period. 
- Subjects allowed stable 
doses of thiopurines, 
mesalamine, or 
corticosteroids ≤ 10mg/d for 
8 weeks before inclusion. 
- An endoscopic score ≥1 at 
baseline sigmoidoscopy was 
mandatory for inclusion. 
 
- Pt excluded if used anti-tumor 
necrosis factor or methtroxate 
treatment within 8 weeks before 
inclusion, or cyclosporine within 4 
weeks before inclusion. 
- An infectious cause of a Ulcerative 
Colitis disease flare 
- Hx of colonectomy, a current 
stoma, life expectancy <12 months, 
pregnancy, and hospital admission 
were exlusion criteria. 
- Pts were not allowed to use 
antibiotics or probiotics within 6 
weeks before inclusion. 
2 - Fecal 
Microbiota 
Transplantation 
from Healthy 
Donors. 
- 2 Duodenal 
Infusions of a 
suspension of 
Donor Feces 
[FMT-D] vs. 2 
Duodenal 
Infusions of a 
suspension of 
Autologous 
Feces [FMT-A]	
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Outcomes Measured 
The outcomes measured in all three studies were patient oriented evidence that matters which is 
clinical remission. The outcomes in the Moayyedi et al. was measured by the Mayo Score which 
is a composite of subscores from four categories, including stool frequency, rectal bleeding, 
findings of flexible proctosigmoidoscopy or colonoscopy, and physician’s global assessment, 
with a total score ranging from 0–12. Within the endoscopic component of the Mayo Score, a 
score of 0 is given for normal mucosa or inactive UC, while a score of 1 is given for mild disease 
with evidence of mild friability, reduced vascular pattern, and mucosal erythema. A score of 2 is 
indicative of moderate disease with friability, erosions, complete loss of vascular pattern, and 
significant erythema, and a score of 3 indicates ulceration and spontaneous bleeding. Mucosal 
healing has been defined as a Mayo endoscopic sub score of 0 or 1 in major trials of biological 
therapies in UC.6 The Moayyedi et al. study determined clinical remission which is defined as 
full Mayo Score <3 and an endoscopic Mayo Clinic Score=0.6 The Rossen et al. study 
determined clinical remission as SCCAI score ≤ 2 in combination with ≥1 point improvement 
on the combined Mayo endoscopic score of the sigmoid and rectum, compared to the baseline 
sigmoidoscopy, 12 weeks after the first treatment.5 The Wei et al. trail determined clinical 
remission was defined as IBDQ >170 and Mayo score <2 in Ulcerative Colitis.7  
Results 
 The Moayyedi et al study was a randomized double blind control study with outcomes 
that were dichotomous data and based on intent to treat. To begin this study there were 85 
patients who were assessed and eligible for the trial. Ten patients from the study were soon 
dropped due to 7 subjects no longer having active disease, 2 for being clostridum dificile- 
positive and 1 withdrew before randomization. So 75 patients were left to be randomized into the 
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placebo group and other half allocated to the FMT trail. 37 patients were in the placebo group 
and 38 patients were in the FMT experimental group. Patients were randomized in this study to 
either receive 50 mL of FMT or a placebo of 50 mL of water given as a retention enema once per 
week for a total of 6 weeks and on the 7th week final Mayo Clinic score, Inflammatory Bowel 
disease questionnaire (IBDQ) and an exit sigmoidoscopy to compare to the baseline scores. 3 
people dropped out from the placebo group and 2 from the FMT experimental group leading to 
70 patients completing the study; 34 completing the placebo trial and 36 completing FMT 
experimental trail. The outcomes were measured for clinical remission at the seventh week after 
treatment. At the of 7 weeks, the clinical remission of Ulcerative Colitis showed a significant 
difference in adequate relief between the placebo group and fecal microbiota transplantation 
experimental group. The proportion of participants in the FMT group that had clinical remission 
was 23.7% whereas 5.4% of the placebo group had clinical remission (Table 2). With p-value of 
.03 is statistically significant there is clinical remission of Ulcerative Colitis given FMT 
compared to placebo.6 
Table 2: Percent of Participants with Clinical Remission of Ulcerative Colitis 6 weeks after Treatment 
 # of Participants in Group # of participants with 
Clinical Remission 
% of participants with 
Clinical Remission 
Fecal Microbiota 
Transplantation [FMT] 
38 9 23.7% 
Placebo 37 2 5.4% 
 
This data from above in Table 2 shows the control event rate [CER] is 5.4%. On the other hand, 
the experiment event rate [EER], which included the FMT GROUP, is 23.7%. From this data the 
numbers needed to treat was 6, so for every 6 patients administered Fecal Microbiota 
Transplantation, one more patient will have remission of Ulcerative Colitis compared to the 
placebo at 7 weeks.  
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 The Rossen et al. study was a randomized double blind control study with dichotomous 
data and based on intention to treat. In the Rossen et al. study, 50 patients were randomized into 
the experimental and control groups and received 2-duoudenal infusions of donor feces from 
healthy host [FMT-D] or 2-duodenal infusions autologous feces [FMT-A], which is the placebo. 
Only 48 patients completed the study; 23 in the FMT-D and 25 in the FMT-A group. The 
infusions were administered at week 0 and week 3 and the outcomes were recorded at the end of 
12 weeks from the SCCAI score and combined Mayo endoscopic score. The proportion of 
participants from the experimental group [FMT-D] group that had clinical remission was 30.4% 
whereas the proportion of the placebo group [FMT-A] that had clinical remission was 20%. So 
based on the p-value of .51 data did not show a statistical significant difference in the clinical 
remission between the placebo and experimental group.5 
Table 3: Percent of Participants with Clinical Remission of Ulcerative Colitis 12 weeks after treatment 
 # of Participants in Group # of participants with 
Clinical Remission 
% of participants with 
Clinical Remission 
FMT-D 23 7 30.4% 
FMT-A 25 5 20% 
  
The data from above shows that the control event rate [CER], which involved the FMT-A 
group is 20%. On the other hand, the experimental event rate [EER], which is the FMT-D group 
is 30.4%. The numbers needed to treat is 10, so for every 10 patients administered fecal 
microbiota transplantation from healthy donor one more patient will have remission of 
Ulcerative Colitis compared to FMT-A group at the end of 12 weeks.  
 In the Wei et al. study, which was a cohort study with outcomes was presented as 
continuous data but was able to be converted into dichotomous data. In this study there were 11 
patients with Ulcerative Colitis that were treated with FMT via colonoscopy or nasojejuanal tube 
infusion. At the end of 4 weeks Inflammatory Bowel Disease Questionnaire, which measured 
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quality of life, and Mayo score was calculated and compared to the baseline. There was no 
control study.7 
Table 4: Results based on Mean Change 4 weeks after Fecal Microbiota Transplantation 
 Baseline Score 4 week after treatment Score 
IBDQ Score 135.50 177.30 
Mayo Score 5.80 1.50 
 
 Based on the table above the mean Mayo score in Ulcerative Colitis patients decreased 
significantly from baseline score of 5.80 to 1.50 which shows dramatic decrease in Mayo Score 
<2. With a p-value <.01, it provides statistical significance that there is clinical remission of 
Ulcerative Colitis 4 weeks post treatment. Also, the IBDQ score rose significantly in patients 
from baseline starting from 135.50 to 177.30 with end IBDQ score >170. With a p-value of 
0.00063, it provides statistical evidence that there is Clinical Remission of Ulcerative Colitis 4 
weeks post treatment. 
Discussion	
	
Ulcerative Colitis is a chronic disease of the colon in which the mucosal lining of the 
colon becomes inflamed which can lead to open sores or ulcers producing pus, mucus, and 
bleeding.2 Currently there is no definitive cure for Ulcerative Colitis but there are medications 
currently out to provide symptomatic relief to treat the disease. In Ulcerative Colitis the 
composition of the microbiota is different in that of a healthy individual in that the diversity is 
lower and contains lower number of Clostridium clusters and Bacteriodes.5 So it is ambiguous if 
this disturbed microbiota is the cause of UC. Fecal microbiota transplantation enriching the gut 
microbiota leading to remission of Ulcerative Colitis.5 
This review compares two randomized, double blind, placebo controlled clinical trials 
and one cohort study in which the Moayyedi et al. and Wei et al. trial proved that Fecal 
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microbiota transplantation is effective in providing clinical remission in patients with active 
Ulcerative Colitis; however, the Rossen et al. trial showed there was no significant statistical 
difference between the experimental [FMT-D] and the placebo [FMT-A] group in inducing 
clinical remission in patients with active Ulcerative Colitis.  
These three articles did contain some limitations in this review. In the Moayeedi et al. 
study, the donor stool was not held as a control as patients either received as frozen or fresh fecal 
sample. Seemed as if frozen stool seemed to be a bit more effective but may be confounded due 
to frozen stool being from Donor B. Patients who received Donor B stool seemed to be most 
effective so not all donor stools effective in treating UC because each stool made of differing 
microbiota. So another way to keep a better control was all patients received fecal sample from 
same host to prevent any variables. Another limitation was not performing colonoscopy at study 
exit and it is possible that patients with extensive colitis have active disease beyond the limit of 
the flexible sigmoidoscope. Another limitation was a small sample size.6 Some limitations in the 
Rossen et al. study is small sample size. Another limitation is inconsistent dosages of fecal 
transplants every 3 weeks. Another limitation in this particular study is making sure all fecal 
matter is composed of similar microbiota to make sure treatment is specific-to-specific 
microbiota, which might yield data on selecting beneficial groups for donation instead of whole 
microbiome transplantation.5 The limitations in the Wei et al. trials are small sample size as well 
as not having a control.7 
Conclusion 
 
 Fecal Microbiota Transplantation does seem to provide effective treatment in causing 
clinical remission of Ulcerative Colitis overall according to the three studies in this review. 
Further study is needed to really evaluate the long term effects with the treatment of Fecal 
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microbiota transplation and to see if it is sustainable in providing long term favorable results. 
Further studies should include larger sample size, controlled donor feces with similar microbiota, 
controlled route of administration either colonoscopy or retention enema approach, and should 
focus on the effect of FMT on clinical remission for periods longer than 4-7 weeks and follow up 
with patient long term for at least 5 years.
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